Published in Exp Hematol Oncol on February 19, 2013
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00550615
DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma. J Exp Med (2015) 1.48
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. Oncotarget (2016) 0.79
Specificity and biologic activities of novel anti-membrane IgM antibodies. Oncotarget (2016) 0.75
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood (2016) 0.75
Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model. Cancer Res (2017) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol (2005) 6.13
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer (2005) 4.66
Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol (1995) 3.35
Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene (2005) 2.36
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol (2006) 2.09
Map kinase signaling pathways and hematologic malignancies. Blood (2003) 2.07
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res (2010) 2.00
The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat Rev Immunol (2010) 1.68
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res (2006) 1.61
Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood (2001) 1.50
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood (2011) 1.49
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.46
Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res (2006) 1.40
Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol (2005) 1.37
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia (2008) 1.36
c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood (2005) 1.36
The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res (2003) 1.27
The role of early growth response gene 1 (egr-1) in regulation of the immune response. J Leukoc Biol (1996) 1.25
Role of EGR1 in regulation of stimulus-dependent CD44 transcription in B lymphocytes. Mol Cell Biol (1996) 1.14
Egr-1 expression in surface Ig-mediated B cell activation. Kinetics and association with protein kinase C activation. J Immunol (1990) 1.10
Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood (2003) 1.09
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica (2010) 1.08
Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics (2009) 1.07
cDNA cloning of mRNAS which increase rapidly in human lymphocytes cultured with concanavalin-A and cycloheximide. Biochem Biophys Res Commun (1985) 1.06
Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia (2007) 1.06
Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol (Dordr) (2011) 1.05
Early growth response transcription factors and the modulation of immune response: implications towards autoimmunity. Autoimmun Rev (2009) 1.04
Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. Blood (2007) 1.01
Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene (2003) 1.01
Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts. Blood (2007) 0.99
JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. J Pathol (2009) 0.97
Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood (2007) 0.96
Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood (2012) 0.95
The role of MAPKs in B cell receptor-induced down-regulation of Egr-1 in immature B lymphoma cells. J Biol Chem (2006) 0.93
Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state. J Biol Chem (2008) 0.93
Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood (2007) 0.90
Early growth response 1 (EGR1): a gene with as many names as biological functions. Cancer Biol Ther (2009) 0.88
Role of Egr-1 gene expression in B cell receptor-induced apoptosis in an immature B cell lymphoma. J Biol Chem (1997) 0.86
CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-mediated growth inhibition by up-regulation of egr-1. Int Immunol (1999) 0.85
Constitutive and inducible levels of egr-1 and c-myc early growth response gene expression in self-renewing B-1 lymphocytes. Cell Immunol (1995) 0.84
Membrane-associated signaling in human B-lymphoma lines. Exp Cell Res (2010) 0.83
Establishment and characterization of a new human lymphoma-derived cell line--HBL-2. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi (1985) 0.77
Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS (2005) 5.51
Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med (2004) 5.36
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med (2004) 4.47
Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology (2003) 2.96
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood (2012) 2.23
A conserved mutation in an ethylene biosynthesis enzyme leads to andromonoecy in melons. Science (2008) 2.11
Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood (2003) 2.06
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood (2005) 1.86
Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol (2002) 1.76
Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res (2009) 1.65
Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood (2010) 1.64
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle (2011) 1.59
Diagnostic accuracy of ACR/EULAR 2010 criteria for rheumatoid arthritis in a 2-year cohort. J Rheumatol (2011) 1.47
Deciphering leukemic B-cell chronic lymphoproliferative disorders. Leuk Lymphoma (2006) 1.46
Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci (2006) 1.44
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood (2007) 1.43
Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res (2006) 1.40
Ezrin tunes T-cell activation by controlling Dlg1 and microtubule positioning at the immunological synapse. EMBO J (2010) 1.40
Reconstructing de novo silencing of an active plant retrotransposon. Nat Genet (2013) 1.40
The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology (2006) 1.39
Evidence of a role for Munc18-2 and microtubules in mast cell granule exocytosis. J Cell Sci (2003) 1.38
Changes over time in the diagnosis of rheumatoid arthritis in a 10-year cohort. J Rheumatol (2009) 1.37
Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology (2006) 1.30
Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. Clin Infect Dis (2008) 1.29
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford) (2013) 1.28
The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family. Oncogene (2003) 1.22
A long-term high-protein diet markedly reduces adipose tissue without major side effects in Wistar male rats. Am J Physiol Regul Integr Comp Physiol (2004) 1.17
National standardization of ZAP-70 determination by flow cytometry: the French experience. Cytometry B Clin Cytom (2007) 1.15
FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem Biophys Res Commun (2002) 1.12
C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer (2007) 1.11
Features of the Arabidopsis recombination landscape resulting from the combined loss of sequence variation and DNA methylation. Proc Natl Acad Sci U S A (2012) 1.10
Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol (2003) 1.08
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica (2010) 1.08
Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. J Rheumatol (2006) 1.07
A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB. BMC Cell Biol (2011) 1.07
SIAH-1 interacts with CtIP and promotes its degradation by the proteasome pathway. Oncogene (2003) 1.06
Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine (2008) 1.05
The mutator pathway is a feature of immunodeficiency-related lymphomas. Proc Natl Acad Sci U S A (2004) 1.04
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol (2012) 1.03
Latent membrane protein 1 regulates STAT1 through NF-kappaB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells. J Virol (2005) 1.03
Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood (2010) 0.99
A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun (2003) 0.99
Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood (2008) 0.98
Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy. Eur J Haematol (2007) 0.98
Vav1 is a component of transcriptionally active complexes. J Exp Med (2002) 0.98
Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study. Biol Blood Marrow Transplant (2010) 0.97
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Gut (2010) 0.95
Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Cytometry B Clin Cytom (2006) 0.95
Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study. Medicine (Baltimore) (2015) 0.94
Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. Blood (2010) 0.94
Hepatitis C-positive donors in heart transplantation. Am J Transplant (2002) 0.94
STAT3 inhibitors for cancer therapy: Have all roads been explored? JAKSTAT (2013) 0.94
Use of hematopoietic progenitor cell count on the Sysmex XE-2100 for peripheral blood stem cell harvest monitoring. Leuk Lymphoma (2007) 0.93
Flow cytometry APC-tandem dyes are degraded through a cell-dependent mechanism. Cytometry A (2009) 0.93
Dimerization of hSiah proteins regulates their stability. Biochem Biophys Res Commun (2006) 0.93
The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia. Blood (2012) 0.92
Characterization of the autocleavage process of the Escherichia coli HtrA protein: implications for its physiological role. J Bacteriol (2008) 0.92
Use of assist devices and ECMO to bridge pediatric patients with cardiomyopathy to transplantation. J Heart Lung Transplant (2002) 0.92
Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine (2011) 0.91
Vav1 and PU.1 are recruited to the CD11b promoter in APL-derived promyelocytes: role of Vav1 in modulating PU.1-containing complexes during ATRA-induced differentiation. Exp Cell Res (2009) 0.91
Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut (2011) 0.90
Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood (2010) 0.90
Intermediate hepatobiliary cells predict an increased risk of hepatocarcinogenesis in patients with hepatitis C virus-related cirrhosis. Gastroenterology (2010) 0.89
A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line. Mol Cancer (2012) 0.89
Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status. Transplantation (2005) 0.88
AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Haematologica (2011) 0.88
Ability of foot radiographs to predict rheumatoid arthritis in patients with early arthritis. J Rheumatol (2004) 0.87
SNAREs and associated regulators in the control of exocytosis in the RBL-2H3 mast cell line. Mol Immunol (2002) 0.87
Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma. Blood (2012) 0.87
Recent trends in early outcome of adult patients after heart transplantation: a single-institution review of 251 transplants using standard donor organs. Am J Transplant (2002) 0.86
Spumous histiocytic oligoarthritis coexisting with systemic Langerhans' cell histiocytosis: case report and literature review. Joint Bone Spine (2009) 0.86
The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. Int J Cancer (2009) 0.86
Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients. Am J Hematol (2014) 0.86
Novel function of STAT1beta in B cells: induction of cell death by a mechanism different from that of STAT1alpha. J Leukoc Biol (2008) 0.84
Performance of hand radiographs in predicting the diagnosis in patients with early arthritis. J Rheumatol (2006) 0.84
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol (2013) 0.84
A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. Anticancer Res (2003) 0.83
Gastrointestinal tuberculosis: 17 cases collected in 4 hospitals in the northeastern suburb of Paris. Gastroenterol Clin Biol (2005) 0.83